HPRA Warns Public After Black-Market Retatrutide Sales Surge in Ireland
TL;DR: HPRA warned (23 Aug 2026) after black-market retatrutide sales in Ireland rose 30-fold, with a hospitalised kidney-injury case reported.
What Did the HPRA Warn About on 23 August 2026?
RTÉ reported on 23 August 2026 that Irish hospitals are seeing a rise in patients presenting with side effects after obtaining black-market retatrutide, the investigational Eli Lilly triple-hormone-receptor agonist still in Phase 3 trials and unapproved for human use anywhere in the world.[1] Professor Donal O'Shea, the HSE's National Clinical Lead for Obesity, described one recent case directly: “We had somebody in at the weekend who was getting retatrutide twice a week in the gym from their personal trainer, and they were in hospital with vomiting and kidney disease.”[1]
The Health Products Regulatory Authority (HPRA), Ireland's medicines regulator, said it has repeatedly warned of the health risks associated with GLP-1-class products obtained outside a licensed pharmacy setting and without prescription and clinical oversight from a doctor.[1] The warning follows an earlier RTÉ Investigates broadcast that filmed a seller in Tuam, Co Galway — not a qualified doctor — marketing retatrutide directly to consumers as “the most powerful weight loss treatment”.[2]
How Is Unapproved Retatrutide Reaching Consumers in Ireland?
Coverage points to two overlapping routes: online and social-media sellers shipping product directly to buyers, and gyms and cosmetic outlets where personal trainers administer injections themselves, with no clinical assessment and no guidance on managing side effects.[1] Prof O'Shea said he was “absolutely shocked” to find retatrutide being distributed this widely through cosmetic outlets rather than remaining confined to Lilly's own clinical trial programme.[3]
No clinical oversight
Personal trainers and unregulated sellers give no assessment of suitability and no advice on managing adverse effects, which clinicians say is a central factor in the hospitalisation cases now being reported.[1]
Unverified product
Retatrutide obtained this way has not passed through any regulator-approved manufacturing or supply chain, meaning dose, purity and even the identity of the active ingredient are unverified at the point of sale.[2]
How Big Is the Seizure Problem, and Is the Product Even What It Claims to Be?
HPRA detention figures show a sharp rise in enforcement activity. Items claiming to be GLP-1-class medicines rose from 1,582 detained in 2024 to 48,752 in 2025 — roughly a 30-fold increase — the large majority presented as unlicensed GLP-1 drops (27,329 items) or microneedle patches (17,170 items), forms in which no licensed GLP-1 medicine is currently marketed.[4]
| Metric | 2024 | 2025 |
|---|---|---|
| GLP-1-claiming items detained | 1,582 | 48,752 |
| Total falsified/illegal medicine units | – | 763,027 |
| Individual seized consignments | Baseline | ~180% higher |
Source: HPRA annual detention reporting, as covered by the Irish Medical Times and HPRA.ie.[4][5]
Testing found mislabelled contents. HPRA laboratory testing of a sample of the detained transdermal patches marketed as containing semaglutide found they did not contain the active ingredient claimed on the packaging.[4] A product sold outside a verified supply chain carries no reliable guarantee that its contents match its label — the same concern we detailed in our coverage of Eli Lilly's own lawsuits against black-market retatrutide sellers, where seized vials were found to contain everything from zero active ingredient to insulin.
Is Retatrutide Legally Approved in Ireland or the UK?
No. Retatrutide (LY3437943) remains an investigational compound completing Eli Lilly's TRIUMPH Phase 3 programme, with no marketing authorisation from the HPRA, MHRA, EMA or FDA.[1] Lilly has said it targets a Q1 2027 Biologics License Application filing once its Phase 3 package and chemistry, manufacturing and controls work are complete — until any regulator formally approves it, retatrutide is available only within Lilly's own trials and its narrow expanded-access pathway.[6]
That regulatory gap is exactly what black-market sellers are exploiting in Ireland, as it is elsewhere. RTÉ's 15 August 2026 analysis of the broader weight-loss drug market noted that demand for GLP-1-class products has consistently outpaced the legitimate, prescribed supply available through Irish pharmacies.[7]
What Should UK and Irish Researchers Take From This?
The HPRA's warning concerns unlicensed sellers supplying black-market product directly for human injection, with no clinical oversight and no verification of what the vial or patch actually contains — the opposite of lawful in vitro research-reagent supply. A genuine research reagent carries no dosing instructions, makes no claim of fitness for human or veterinary use, and is sold with a certificate of analysis rather than a promise of therapeutic performance. This mirrors the distinction we drew in our coverage of whether research peptides are legal in the UK and of social-media-driven demand for unregulated peptides.
Velox Peptides supplies retatrutide strictly as an HPLC-verified in vitro research reagent, with batch documentation available on request and no dosing guidance of any kind.
Retatrutide is referenced here for regulatory-news context only. Where supplied by Velox Peptides, it is a research reagent, not a medicine, and has not been evaluated by the HPRA, MHRA or FDA in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- RTÉ. Public warned not to take unapproved weight-loss drug. 23 August 2026. rte.ie
- RTÉ Investigates. Sale of unapproved US weight loss trial drug exposed in Ireland. 9 December 2024. rte.ie
- The Irish Times. Chief obesity clinician Prof Donal O'Shea ‘shocked’ at prevalence of black market ‘skinny jabs’. 9 December 2024. irishtimes.com
- Irish Medical Times. 30-fold rise in seizures of illegal weight-loss drugs. 24 March 2026. imt.ie
- HPRA. Over 750,000 units of illegal medicines detained by the HPRA in 2025. hpra.ie
- CNBC. Eli Lilly will file for approval of retatrutide obesity drug in 2027. 23 July 2026. cnbc.com
- RTÉ. Weight loss drugs – can the demand be contained? 15 August 2026. rte.ie
Frequently Asked Questions
What did the HPRA warn about on 23 August 2026?
RTÉ reported on 23 August 2026 that a leading obesity consultant, Professor Donal O'Shea, said hospitals are seeing a rise in patients presenting with side effects after obtaining black-market retatrutide, including one patient hospitalised with vomiting and kidney injury after receiving injections twice weekly from a personal trainer. The HPRA has repeatedly warned that GLP-1-class products obtained outside a licensed pharmacy, without prescription and clinical oversight, carry serious health risks.
How much has black-market weight-loss drug seizure activity risen in Ireland?
HPRA detention data show products claiming to be GLP-1 medicines rose from 1,582 detained items in 2024 to 48,752 in 2025, roughly a 30-fold increase, mostly unlicensed drops and microneedle patches. The HPRA detained 763,027 dosage units of falsified and illegal medicines overall in 2025, an approximately 180% rise in individual seized consignments compared with 2024.
Is retatrutide approved for use in Ireland or the UK?
No. Retatrutide (LY3437943) is an investigational Eli Lilly compound still completing Phase 3 trials, with no marketing authorisation from the HPRA, MHRA, EMA or FDA anywhere in the world. It cannot lawfully be sold as a medicine in Ireland, the UK, or elsewhere, and any product marketed for human injection or weight loss is being sold outside the law regardless of how it is labelled.
Does this affect Velox Peptides' research-reagent retatrutide?
No. This article reports on unlicensed sellers, including personal trainers and cosmetic outlets, supplying black-market retatrutide directly for human injection with no clinical oversight. Velox Peptides supplies retatrutide strictly as an HPLC-verified in vitro research reagent for qualified UK researchers, with no dosing instructions and no claims fit for human or veterinary use.
Why is testing showing some seized products don't even contain the drug claimed on the label?
HPRA laboratory testing of detained transdermal patches marketed as containing semaglutide found they did not contain the active ingredient claimed on the packaging. Unlicensed peptide and GLP-1 products sold outside a verified supply chain carry no reliable guarantee that the vial or patch contains what the label states, at the concentration stated, or is free of contamination.